Results 181 to 190 of about 686,182 (220)
Some of the next articles are maybe not open access.
Human Pathology, 2005
Anaplastic large cell lymphoma (ALCL) is an aggressive large T- or null-cell lymphoma. Most ALCLs arising in children and young adults express a constitutively active receptor tyrosine kinase, anaplastic lymphoma kinase (ALK). Anaplastic large cell lymphomas lacking ALK are clinically heterogeneous and their pathogenesis is unknown.
Mary Ann, Thompson +10 more
openaire +2 more sources
Anaplastic large cell lymphoma (ALCL) is an aggressive large T- or null-cell lymphoma. Most ALCLs arising in children and young adults express a constitutively active receptor tyrosine kinase, anaplastic lymphoma kinase (ALK). Anaplastic large cell lymphomas lacking ALK are clinically heterogeneous and their pathogenesis is unknown.
Mary Ann, Thompson +10 more
openaire +2 more sources
Anaplastic Lymphoma Kinase in Human Cancer
Critical Reviews™ in Oncogenesis, 2012The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent clinical trials with ALK inhibitors provide promise for patients harboring oncogenic ALK lesions. This review will discuss our current understanding of ALK in human cancer and the implication of recent results for ...
Christina, Schonherr +2 more
openaire +2 more sources
The anaplastic lymphoma kinase in the pathogenesis of cancer
Nature Reviews Cancer, 2008Tyrosine kinases are involved in the pathogenesis of most cancers. However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas. The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many molecular mechanisms.
CHIARLE, Roberto +4 more
openaire +3 more sources
2019
Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase, which is a member of the insulin receptor superfamily. Fusions in ALK result in constitutively activated signaling which is susceptible to inhibition by ALK tyrosine kinase inhibitors (TKIs). In this chapter we are describing management of patients with ALK-fused lung cancer.
Nicolas A. Villanueva +2 more
openaire +1 more source
Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase, which is a member of the insulin receptor superfamily. Fusions in ALK result in constitutively activated signaling which is susceptible to inhibition by ALK tyrosine kinase inhibitors (TKIs). In this chapter we are describing management of patients with ALK-fused lung cancer.
Nicolas A. Villanueva +2 more
openaire +1 more source
Anaplastic lymphoma kinase proteins and malignancy
Current Opinion in Hematology, 2001The anaplastic lymphoma kinase (ALK) gene fuses to the nucleophosmin (NPM) gene as a result of a (2;5) translocation associated with a subtype of human lymphoma (initially designated anaplastic large cell lymphoma [ALCL] or Ki-1/CD30-positive lymphoma).
K, Pulford, S W, Morris, D Y, Mason
openaire +2 more sources
Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma [PDF]
Hematology, 2019 Anaplastic lymphoma kinase negative anaplastic large cell lymphoma (ALK- ALCL) is a definite entity in the WHO 2016 Classification that represents 2-3% of non-Hodgkin lymphoma (NHL) and 12% of T-cell NHL cases. ALK- ALCL lacks ALK protein expression, but expresses CD30 and has morphologic features similar to ALK positive anaplastic large cell lymphoma (
Ming-Zhi Zhang
exaly +3 more sources
Inhibitors of the anaplastic lymphoma kinase
Expert Opinion on Investigational Drugs, 2012Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase normally expressed in the developing nervous tissue. Genetic alterations of ALK are associated with a number of cancers, including anaplastic large cell lymphoma (ALCL) and a subset of non-small cell lung cancer (NSCLC).
openaire +3 more sources
Crizotinib: An Anaplastic Lymphoma Kinase Inhibitor
Future Oncology, 2011Crizotinib is an oral small-molecule inhibitor of ALK and c-Met tyrosine kinases that is being developed by Pfizer. ALK mutations or gene rearrangements result in growth factor-independent ALK activation. Most of the available clinical data with crizotinib are in patients with tumors that have an activated ALK, and the drug has shown very promising ...
Shirish M, Gadgeel, Gerold, Bepler
openaire +2 more sources
The anaplastic lymphoma kinase testing conundrum
Expert Review of Molecular Diagnostics, 2015Given the excellent results of the clinical trials with anaplastic lymphoma kinase (ALK) inhibitors, the importance of accurately identifying ALK-positive lung carcinoma patients has never been greater. It brings with it a pressing need for harmonized development of companion diagnostics, for economic, scientific and medical reasons.
Esther, Conde +2 more
openaire +2 more sources
2015
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) having an extracellular, a single transmembrane, and an intracellular domain containing the tyrosine kinase activity. ALK belongs to the insulin receptor subfamily of RTKs, most closely related to leukocyte tyrosine kinase receptor. It localizes mostly in neuronal cells and may play a
openaire +2 more sources
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) having an extracellular, a single transmembrane, and an intracellular domain containing the tyrosine kinase activity. ALK belongs to the insulin receptor subfamily of RTKs, most closely related to leukocyte tyrosine kinase receptor. It localizes mostly in neuronal cells and may play a
openaire +2 more sources